The Children's Hospital Corporation

The Children's Hospital Corporation, doing business as Boston Children's Hospital, acts as a federal grant recipient and research prime across the National Institutes of Health and allied health agencies, with a mission-driven portfolio focused on pediatric medical research, biomedical discovery, and translational science rather than vendor-supplied goods or services. The organization is a nonprofit pediatric teaching hospital and Harvard Medical School affiliate operating as a federal research institution based in Boston, Massachusetts. Boston Children's Hospital does not compete under set-asides and receives no SBA designations; it operates in full-and-open federal grant and research contract space dominated by NIH funding mechanisms.

Boston Children's Hospital's federal footprint reflects a research enterprise centered on pediatric health discovery. The organization acts as prime recipient on approximately 2,134 federal grants and research awards spanning NIH institutes, the Defense Health Agency, CDC, and other health-focused federal agencies. Recent representative awards include a $27.858 million CDC surveillance contract (awarded September 2026) to track severe invasive group A Streptococcus in U.S. children; a $7.999 million Defense Health Agency grant (August 2026) on therapeutic gene editing for sickle cell disease; and a $3.637 million National Institute of Neurological Disorders and Stroke award (August 2026) investigating pro-resolving lipid mediators as therapeutic targets for endometriosis-associated pain. The organization also holds a $306,403 cooperative agreement (August 2026) to establish and operate the Pediatric Bone Marrow Failure Network, a national clinical research infrastructure uniting the North American Pediatric Aplastic Anemia Consortium with the Rare Disease Clinical Research Network. Across these work streams, Boston Children's Hospital delivers pediatric-focused basic and clinical research, biomarker discovery, clinical trial design and execution, epidemiological surveillance, and translational genomics services.

Customer concentration is heavily weighted toward NIH institutes. The National Institute of Allergy and Infectious Diseases leads the agency portfolio by combined potential value ($73.3 million across 295 awards, representing a 24% share of total potential value), followed by the broader NIH pool of general research support ($39.1 million across 550 awards). The National Heart, Lung, and Blood Institute ($12.3 million across 286 awards) and the National Institute of Diabetes and Digestive and Kidney Diseases round out the top four by dollars. This concentration reflects Boston Children's Hospital's deep positioning in pediatric disease research across infectious disease, cardiovascular biology, metabolic disorders, neurodevelopment, and oncology.

In its subcontractor role, Boston Children's Hospital performs collaborative research work under prime recipients including Northeastern University (psychophysical testing for amblyopia studies), Brigham & Women's Hospital (genomic and imaging analyses for lupus and lung disease research), Hugo W. Moser Research Institute at Kennedy Krieger (participation in the Cerebral Neuronal Ceroid Lipofuscinosis Career Development and Research Program), and numerous academic medical centers in NIH-managed consortia addressing rare disease natural history, genetic architecture, and clinical trial outcomes. The organization contributes molecular biology, genomic analysis, clinical phenotyping, neuroimaging interpretation, and biospecimen processing.

Activity has been variable year-to-year in the SCI-reportable subset (FY2022–FY2025), with $23.8 million in invoiced federal service contract revenue in FY2022, a gap in FY2023, a spike to $28.1 million in FY2024, and minimal activity in FY2025. Government-paid hourly rates on service contracts ran a median of $212.65/hr, with a range from roughly $113/hr at the 10th percentile to over $1,061/hr for senior personnel. The organization does not rely on subcontractors on its SCI-reportable prime work; sub-hours share is zero. Total federal dollars obligated across all awards ($6.67 billion) significantly exceed combined potential value ($303.2 million), reflecting a mature, long-running grant and research contract portfolio with many previously obligated awards now in execution or completion phases. A recompete cliff of $45.1 million in combined potential value faces completion within the next twenty-four months, creating renewal and competition opportunity.

Boston Children's Hospital's federal positioning is fundamentally that of a research institution and clinical care provider delivering investigator-initiated NIH biomedical research across pediatric disease domains. The organization does not manufacture or procure goods as a primary function; rather, it performs labor-intensive basic science, clinical research, translational medicine, and data analysis services. Federal competitive positioning turns on research productivity, clinical acumen, institutional IRB and regulatory infrastructure, biospecimen and data repositories, and the scientific reputation of individual investigators and research teams, not on procurement agility or supply chain capability.